Navigation Links
Bionovo Announces 2010 Highlights and Year-End Financial Results
Date:3/15/2011

anism of estrogen receptor beta. As a leading pharmaceutical company in the mediation of estrogen receptors, such studies are critical for potential new products for the Company.
  • potential estrogen receptor modulating drugs for treating menopausal conditions. This is, essentially, a potential roadmap for further pipeline candidates in the Bionovo women's health platform.
  • Menerba's effect on neural pathways related to temperature regulation, further strengthening the Company's understanding of the mechanism of action for Menerba.
  • the discovery of distinct classes of genes regulated by estrogen receptor beta, adding even more to Bionovo's demonstrated understanding of the mechanisms of estrogen receptors.
  • A proprietary, innovative method of high throughput LC-MS/MS tandem quantification of multiple bioactive compounds was described, which is essential to the development of Menerba.
  • A fundamental patent was issued for Bezielle™ in the treatment of metastatic breast cancer.
  • In 2010, the Company was active in accessing the capital markets and government grants for needed funding:
  • In December, the Company filed its intent with the SEC to launch a fully committed underwritten public offering. This offering closed in February 2011 for a total of $27.4 million in net proceeds.
  • In November, the Company announced that it had received a Qualifying Therapeutic Discovery Program (QTDP) grant of $489,000 from the federal government for the Menerba and Bezielle programs.
  • In October, the Company announced the closing of a registered direct offering with select investors for net proceeds of $2.5 million. Although not noted at the time, these fundamental investors were integral to the later, larger, underwritten offering that closed in February of 2011.
  • In September, the Company announced that it had received an NIH grant of $174,000 to develop drugs for the treatment of female-specific obesity
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    2. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    3. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
    4. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
    5. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
    6. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
    7. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
    8. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    9. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
    10. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
    11. Bionovo to Raise $3 Million Through Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
    (Date:4/16/2015)... 16, 2015 Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, announced today that ... Commission an Annual Report on Form 20-F that included ... 2014. An electronic version of Mindray,s Annual Report ... relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
    (Date:4/16/2015)... 2015 Mallinckrodt plc (NYSE: MNK ... that it has completed its acquisition of Ikaria, ... billion. The Ikaria acquisition extends Mallinckrodt,s footprint in ... neonatal critical care with INOMAX ® (inhaled ... highly vulnerable patient population. It also accelerates Mallinckrodt,s ...
    Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5
    ... FRANCISCO, Oct. 30 CCBR-SYNARC, the world,s leading provider ... center services to the pharmaceutical and biotechnology industries, announced ... for use in imaging clinical trials. , SYNARC has ... 2004. With the release of the enhanced SynarcConnect(SM) ...
    ... Inc. announced the re-launch of its changing possibilities ... Web site and a new community on Facebook®. People ... Nordisk is committed to helping this community realize that ... new online resources were created to engage and connect ...
    Cached Medicine Technology:CCBR-SYNARC Expands Electronic Data Capture Capabilities 2Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3
    (Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
    (Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed Royce ... 1849 in congress on April 16, 2015 in an ... with the genetic disease. , The bill, similar ... first to create a federally led and financed initiative ... telangiectasia. This would effectively prevent premature death and disability ...
    (Date:4/17/2015)... Most dental patients are not aware ... made overseas by foreign dental laboratories, according to the ... in more than 40 states by their respective state ... Dental Laboratories has created the “What’s In ... about the consequences that could be associated with using ...
    (Date:4/17/2015)... 2015 Scientists from the Icahn ... of U.S. and Venezuelan researchers, have discovered the ... among an isolated tribe of Yanomami Amerindians in ... in the Yanomami, previously unexposed to antibiotics or ... that of people living in industrialized countries, and ...
    (Date:4/17/2015)... 2015 Compare-autoinsurance.org has released a new ... online auto insurance quotes . , The online ... for their cars. Drivers should always compare multiple car ... insurance market is a competitive one, which means that ... , It is now possible to compare online ...
    Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2
    ... developed by an immunologist Dr Brendan O'Sullivan of Brisbane, for ... skyrocketing rates// of medicines that is available for diabetes in ... UQ's Centre for Immunology and Cancer Research (CICR) are developing ... in obesity -- a common precursor to diabetes, reports foodconsumer.org. ...
    ... a million lives owing to treatment costs that very many ... Asia and Africa seem to be at the receiving end. ... coming out with a facility that would enable mass production ... capacity to lower the costs of each dose by 25 ...
    ... Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' ... patients//, suffering from lung cancer. ,The Managing Director ... tablet taken once a day and has the potential ... patients with locally advanced or metastatic Non-Small Cell Lung ...
    ... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
    ... methods it ahs been found that survival rates following ... when emergency medical// personnel used a new form of ... Center. ,Cardiocerebral Resuscitation, is how this new approach is ... procedures. , ,In the words of Michael J. ...
    ... at assuming the role of a doctor but pretty bad ... University// of Technology has revealed that nearly half of all ... almost always higher than it should be. ,Over medication ... of overmedication have risen from 12% in 1987 to 33 ...
    Cached Medicine News:Health News:Type 2 Diabetes Could Be Tackled Using Curry Colouring and Fat Mix 2Health News:Paramedics save more lives following unconventional rules 2
    Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
    Light weight adjustable trial frame, adult...
    Classic Trial Frames UB3 that has long set the standard....
    Non Sterile surgical blade....
    Medicine Products: